Scholarlink

Introduction <p>Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited treatment options. Phosphoglycerate kinase 1 (PGK1), with both glycolytic and kinase activities, has been implicated in tumor progression, but its therapeutic potential in ESCC remains unclear.</p> Methods <p>We assessed PGK1 by genetic knockdown and developed compd 25 − 4, a structure-based small-molecule inhibitor. Biochemical and cellular assays determined its activity against PGK1 and ESCC proliferation. Mechanisms were explored through cellular glycolysis analysis, autophagy assessment, reverse-phase protein array (RPPA) analysis, and signaling pathway characterization.</p> Results <p>PGK1 knockdown significantly impaired ESCC cell growth both in vitro and in vivo, supporting its role as a therapeutic target. Compd 25 − 4 inhibited PGK1 glycolytic activity with nanomolar potency (IC<sub>50</sub> = 41 nM) and demonstrated &gt; 5-fold selectivity toward EGFR-positive ESCC cells compared to EGFR-negative cells. Beyond glycolysis inhibition, compd 25 − 4 suppressed PGK1 kinase-mediated PRAS40 signaling and induced autophagy-dependent degradation of EGFR. This dual mechanism of action simultaneously disrupted cancer metabolism and EGFR-driven oncogenic signaling, leading to enhanced therapeutic efficacy.</p> Conclusions <p>Our findings establish PGK1 as a promising therapeutic target in ESCC and identify compd 25 − 4 as a potent chemical tool for probing PGK1’s dual enzymatic functions. By concurrently blocking glycolysis and promoting autophagy-mediated EGFR degradation, targeting PGK1 provides a novel therapeutic strategy for EGFR-positive ESCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Juan Ge,
  • Yongfei Chen,
  • Zongru Jiang,
  • Shuang Qi,
  • Jie Hu,
  • Beilei Wang,
  • Aoli Wang,
  • Qingsong Liu,
  • Hong Wu,
  • Wenchao Wang,
  • Jing Liu

摘要

Introduction

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited treatment options. Phosphoglycerate kinase 1 (PGK1), with both glycolytic and kinase activities, has been implicated in tumor progression, but its therapeutic potential in ESCC remains unclear.

Methods

We assessed PGK1 by genetic knockdown and developed compd 25 − 4, a structure-based small-molecule inhibitor. Biochemical and cellular assays determined its activity against PGK1 and ESCC proliferation. Mechanisms were explored through cellular glycolysis analysis, autophagy assessment, reverse-phase protein array (RPPA) analysis, and signaling pathway characterization.

Results

PGK1 knockdown significantly impaired ESCC cell growth both in vitro and in vivo, supporting its role as a therapeutic target. Compd 25 − 4 inhibited PGK1 glycolytic activity with nanomolar potency (IC50 = 41 nM) and demonstrated > 5-fold selectivity toward EGFR-positive ESCC cells compared to EGFR-negative cells. Beyond glycolysis inhibition, compd 25 − 4 suppressed PGK1 kinase-mediated PRAS40 signaling and induced autophagy-dependent degradation of EGFR. This dual mechanism of action simultaneously disrupted cancer metabolism and EGFR-driven oncogenic signaling, leading to enhanced therapeutic efficacy.

Conclusions

Our findings establish PGK1 as a promising therapeutic target in ESCC and identify compd 25 − 4 as a potent chemical tool for probing PGK1’s dual enzymatic functions. By concurrently blocking glycolysis and promoting autophagy-mediated EGFR degradation, targeting PGK1 provides a novel therapeutic strategy for EGFR-positive ESCC.